Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:35 PM EDT

Kamada (KMDA) Research & Development (2012 - 2026)

Kamada's (KMDA) quarterly Research & Development came in at $2.2 million in Q2 2026, down 31.66% on a YoY basis from $3.2 million in Q2 2025, and up 0.87% quarter-over-quarter from $2.2 million in Q1 2026.

Analysis

Kamada (KMDA) Research & Development (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Research & Development for 15 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Research & Development fell 31.66% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $9.9 million (down 26.87% YoY), and the FY2025 full-year result was $13.0 million, down 14.42% from the prior year.
  • Research & Development improved to $2.2 million in Q2 2026 per KMDA's latest filing, from $2.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.8 million in Q2 2024 and bottomed at $2.2 million in Q1 2026.
  • Historically, Research & Development has averaged $3.3 million across 5 years, with a median of $3.2 million in 2023.
  • The sharpest annual moves came in 2022 and 2026: Research & Development jumped 68.19% in 2022, then plunged 48.63% in 2026.
  • Over 5 years, Research & Development stood at $3.0 million in 2022, then increased by 8.29% to $3.2 million in 2023, then decreased by 17.47% to $2.7 million in 2024, then rose by 8.27% to $2.9 million in 2025, then dropped by 23.98% to $2.2 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods registered $2.2 million, $2.2 million, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Amgen 211.77 Bn 197.79 Bn 7.24 Bn 1.87 Bn
2 Gilead Sciences 181.13 Bn 177.95 Bn 6.22 Bn 1.76 Bn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn 993.80 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.89 Bn 3.93 Bn 1.63 Bn
5 Argenx Se 61.56 Bn 56.38 Bn 1.37 Bn -486.00 Mn
6 Moderna 54.38 Bn 49.24 Bn 52.00 Mn 651.00 Mn
7 Alnylam Pharmaceuticals 34.44 Bn 31.13 Bn 992.69 Mn 413.13 Mn
8 Biogen 31.17 Bn 29.89 Bn 1.96 Bn 529.60 Mn
9 Roivant Sciences 30.12 Bn 30.12 Bn 1.16 Mn 202.02 Mn
10 Kamada 473.28 Mn 403.14 Mn 22.47 Mn 2.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.20 Mn
Mar 31, 2026 2.18 Mn
Dec 31, 2025 2.89 Mn
Sep 30, 2025 2.64 Mn
Jun 30, 2025 3.22 Mn
Mar 31, 2025 4.25 Mn
Dec 31, 2024 2.67 Mn
Sep 30, 2024 3.41 Mn
Jun 30, 2024 4.80 Mn
Mar 31, 2024 4.30 Mn
Dec 31, 2023 3.24 Mn
Sep 30, 2023 3.18 Mn
Jun 30, 2023 4.28 Mn
Mar 31, 2023 3.23 Mn
Dec 31, 2022 2.99 Mn
Sep 30, 2022 3.12 Mn
Jun 30, 2022 2.64 Mn
Mar 31, 2022 4.42 Mn
Dec 31, 2021 3.45 Mn
Sep 30, 2021 2.55 Mn